After increasing in pre-market trading, Novo Nordisk (NVO) U.S.-listed stocks fell after the market opened Wednesday as third-quarter sales fell short of estimates despite continued growth in weight-loss drugs Ozempic and Wegovy.

The Danish drugmaker declared 71.31 billion Danish crown ($10.24 billion) in sales— a 21% jump from the same period last year — but still just shy of DKK72.17 billion ($10.36 billion) analysts expectedaccording to estimates compiled by Visible Alpha. Despite sales failure, Novo Nordisk net income of DKK 27.3 billion was higher than the DKK 26.66 billion expected by analysts.

Sales of the company’s obesity and diabetes drugs jumped 25% from the same period last year, while sales in North America jumped 31% during the quarter. THE the company faced questions US lawmakers explaining why its products are so much more expensive in the US than they European countries.

Annual Outlook Reduced Top and Bottom

“Sales growth is driven by increasing demand for our GLP-1-based diabetes and obesity treatments, and we are serving more patients than ever,” Novo Nordisk CEO Lars Fruergaard Jørgensen said.

The company also reduced its orientation for the whole yearforecasting sales growth of between 23% and 27%, with the high- and low-end segments slightly narrower than the 22% to 28% previously projected. The same adjustment was made to operating profit projections, as Novo Nordisk now expects the metric to increase by 21% to 27% year-over-year, compared to the previous range of 20% to 28%.

U.S.-traded shares of Novo Nordisk were down 3% Wednesday morning.